Last updated on March 2020

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine


Brief description of study

The main purpose of this study is to determine the safety and efficacy of the study drug galcanezumab in participants 6 to 17 years of age with episodic migraine.

Clinical Study Identifier: NCT03432286

Find a site near you

Start Over

Headache Center of Puerto Rico

San Juan, Puerto Rico
2.9miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.